Propanc Biopharma Secures $100 Million Financing to Advance Cancer Stem Cell Therapy PRP Toward First-in-Human Trial
核心洞察
Propanc Biopharma (搜索) has secured up to $100 million in financing from Hexstone Capital (搜索) to accelerate development of its lead cancer therapy PRP, which targets cancer stem cells through proenzyme activation.
The company plans to initiate a First-in-Human study for PRP in the second half of 2026, focusing on preventing recurrence and metastasis in solid tumor cancers.
The financing structure includes convertible preferred stock and warrants, with the company also pursuing a digital asset acquisition strategy to build a $100 million treasury within twelve months.
Propanc Biopharma (搜索) has announced a strategic financing agreement worth up to $100 million with Hexstone Capital (搜索) LLC to accelerate the development of its novel cancer therapy targeting cancer stem cells. The Melbourne-based biopharmaceutical company plans to use the funding to advance its lead product candidate PRP toward a First-in-Human study scheduled for the second half of 2026.
Novel Proenzyme Technology Targets Cancer Stem Cells
Propanc's therapeutic approach centers on preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through the activation of pancreatic proenzymes. The company's lead product candidate PRP is designed to address the root cause of cancer proliferation and spread, representing a departure from conventional cancer treatments.
"We are entering a transformative phase for the Company as we work on building our digital asset base and strengthening our balance sheet, which will enable us to accelerate our unique proenzyme technology to clinical development and beyond," said James Nathanielsz, Propanc's Chief Executive Officer.
The therapy is based on the concept that pancreatic enzymes, which naturally stimulate essential biological reactions in the body, may serve as a natural defense mechanism against cancer. The company's approach specifically targets patients suffering from pancreatic, ovarian, and colorectal cancers.
Financing Structure and Digital Asset Strategy
Under the financing agreement with Hexstone Capital (搜索), Propanc received an initial investment of $1 million through the issuance of 100 shares of newly designated Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000.
The preferred stock is convertible into common stock at an initial conversion price of $5.00 per share, representing a 28% premium over the company's recent closing price of $1.78. The conversion terms include variable alternative conversion prices and are subject to a 4.99% beneficial ownership limitation.
Additionally, Propanc issued 9,900 warrants to Hexstone, each entitling the purchase of one share of preferred stock at approximately $10,000 per share, totaling up to $99 million in potential funding. The warrants are exercisable immediately and remain valid for 12 months. Subject to equity conditions and beneficial ownership limits, the company may call up to 500 warrants per calendar month, allowing the exercise of up to $5 million in preferred stock monthly.
Expanding Treatment Applications
Nathanielsz outlined the company's broader vision for the proenzyme technology platform: "Our business model will revolutionize the way we fund and grow our intellectual property portfolio, fast track our R&D processes and expand our development program so that we can target not only patients suffering from metastatic cancer from solid tumors, but several chronic diseases based upon the mechanism of action of proenzyme therapy."
The company aims to leverage Hexstone's previous investments in Digital Asset Treasury companies to build its own treasury to a value of $100 million or more within the next twelve months. Hexstone Capital (搜索) is a family office that has invested in companies across various digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ.
Clinical Development Timeline
With the secured funding, Propanc plans to accelerate its research and development pipeline, with PRP entering a First-in-Human study in the second half of 2026. This represents a significant milestone for the company's novel approach to cancer treatment, which focuses on preventing recurrence and metastasis rather than solely targeting existing tumors.
The financing agreement positions Propanc to advance its proenzyme technology platform while simultaneously building a digital asset treasury strategy, reflecting the evolving landscape of biotech financing where companies are increasingly exploring alternative funding and treasury management approaches.